Skip to main content

Table 3 Results from clinical field study on efficacy of ProHeart® 12 against Dirofilaria immitis in dogs

From: ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months

Treatment group

Study day

Adult HW antigen test

Microfilaria test

Total no. of dogs

Prevention rate

(Day 365)

Prevention rate

(Day 480)

Prevention rate

(Day 605)

Overall prevention rate

Negative

Positive

Negative

Positive

No. of dogs

%

No. of dogs

%

No. of dogs

%

No. of dogs

%

Heartgard® Plus (T01)

365

215

98.6

3

1.4

216

99.1

2

0.9

218a

98.6% (215 of 218)

99.5% (208 of 209)

100% (201 of 201)

98.2% (214 of 218)

480

208

99.5

1

0.5

208

99.5

1

0.5

209b

605

201

100

0

0

201

100

0

0

201

ProHeart® 12 (T02)

365

235

100

0

0

235

100

0

0

235

100% (235 of 235)

100% (226 of 226)

100 (222 of 222)

100%c (235 of 235)

480

226

100

0

0

226

100

0

0

226

605

222

100

0

0

222

100

0

0

222

  1. aThree dogs (treated with Heartgard® Plus) were withdrawn after testing positive for adult HW antigen and/or microfilariae on Day 365
  2. bOne dog (treated with Heartgard® Plus) was withdrawn after testing positive for adult HW antigen and/or microfilariae on Day 480
  3. cProHeart® 12 significantly better than Heartgard® Plus (P = 0.0367)